Maha Katabi

General Partner at Sofinnova Investments, Inc.

Maha Katabi

Maha Katabi

General Partner at Sofinnova Investments, Inc.

Overview
RelSci Relationships

383

Number of Boards

14

Birthday

1974

Age

47

Number of Awards

1

Relationships
RelSci Relationships are individuals Maha Katabi likely has professional access to. A relationship does not necessarily indicate a personal connection.

Senior Partner at Sectoral Asset Management, Inc.

Relationship likelihood: Strong

Co-Founder at Apellis Pharmaceuticals, Inc.

Relationship likelihood: Strong

Co-Founder at Apellis Pharmaceuticals, Inc.

Relationship likelihood: Strong

Former President at MSI Methylation Sciences, Inc.

Relationship likelihood: Strong

Chief Executive Officer & Director at Gyroscope Therapeutics Ltd.

Relationship likelihood: Strong

Partner at Omega Fund Management LLC

Relationship likelihood: Strong

Partner at Sectoral Asset Management, Inc.

Relationship likelihood: Strong

Director at Sectoral Asset Management, Inc.

Relationship likelihood: Strong

Co-Founder, Chairman & Chief Executive Officer at Sectoral Asset Management, Inc.

Relationship likelihood: Strong

Senior Finance Executive at Sectoral Asset Management, Inc.

Relationship likelihood: Strong

Paths to Maha Katabi
Potential Connections via
Relationship Science
You
Maha Katabi
General Partner at Sofinnova Investments, Inc.
Education
Ph.D. in Pharmacology
Career History
Partner
2008 - 2018

Sectoral Asset Management specializes in managing global portfolios that invest in the healthcare sector. The firm employs a bottom-up investment approach that can be categorized as growth at a reasonable price (GARP). Investments are selected using a focused stock selection process based on primary research of company fundamentals and close contacts with company management to assess their scientific, business, financial and ESG aspects. Specific areas of interest include: Pharmaceuticals, Biotechs, Life Science Tools and Services, Medtechs and Healthcare Providers and Services, Healthcare Equipment and Supplies, and Healthcare Technology. Covered companies are blue-chips, main index constituents and companies with innovative programs identified through research and industry contacts, including recent IPOs. The investment process encompasses stock selection, portfolio construction and risk management.

Associate
1999 - Prior

T²C² seeks to identify (in universities, research centers and industry) business opportunities and turn them into real businesses. They invest in health sciences, with an emphasis on biotechnology, pharmaceuticals and medical equipment.Criteria that are necessary for the selection of a project are: excellent quality of science and technology, complementarities and equilibrium of the team, intellectual property and market potential.

Vice President
2004 - 2007

Ventures West Management invests in early-stage technology companies across Canada. They focus on investments in biotechnology, clean technology and communications. Ventures West Management is an active value-added venture capital partner. The firm contributes resources to ensure that portfolio companies build value. Ventures West often has representation on the board of directors of their portfolio companies. The firm looks for companies with experienced management teams, competitive advantages and attractive markets. They target early-stage companies that are seeking seed or Series A funding. The firm also looks for companies with the potential for a profitable exit within 4 to 6 years

Boards & Committees
Director
2021 - Current
Non-Executive Director
2021 - Current
Director
2020 - Current
Awards & Honors
CFA (Chartered Financial Analyst)
This web site is not endorsed by, directly affiliated with, maintained, authorized, or sponsored by Maha Katabi. The use of any trade name or trademark is for identification and reference purposes only and does not imply any association with the trademark holder. The Presence of Maha Katabi's profile does not indicate a business or promotional relationship of any kind between RelSci and Maha Katabi.